STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3262 by analyst upside · 2026-06-27
AMPH
Amphastar Pharmaceuticals, Inc.
Healthcare · Market Cap $960M · P/E 13.1x
ANALYST PRICE TARGET
+4.8%
implied upside to consensus target
Current Price $21.78
Consensus Target $22.83
Bull Target $30.0
Bear Target $19.0
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
2
Hold
3
Sell
0
52-Week Low $16.65
52-Week High $31.26
YTD Return -17.7%
FUNDAMENTALS
Market Cap $960M
P/E Ratio (TTM) 13.1x
Forward P/E 6.9x
EPS (TTM) $1.66
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $721M
Profit Margin 11.0%
52-WEEK RANGE
52-Week Low $16.65
52-Week High $31.26
Current Price $21.78
Bear Target $19.0
Bull Target $30.0
● Now $21.78 ● Target $22.83
TRADING DATA
Avg Volume 616K
YTD Return -17.7%
Analyst Count 6
Consensus Buy
Upside to Target +4.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Amphastar Pharmaceuticals, Inc. (AMPH) is currently trading at $21.78 with a Wall Street consensus price target of $22.83, implying potential upside of 4.8% over the next 12 months. 6 analysts currently cover AMPH, with a consensus rating of Buy — 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $19.0.

AMPH operates in the Healthcare sector with a market capitalisation of $960M. The stock is down 17.7% year-to-date and is currently trading near the lower end of its 52-week range of $16.65 – $31.26.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AMPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-06-03 Building track record
Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2026-05-14 Building track record
Piper Sandler reit
Neutral → Neutral 2026-05-11 14% win rate (7 calls)
Needham ↓ Downgrade
Buy → Hold 2026-05-08 20% win rate (5 calls)
Jefferies ↓ Downgrade
Buy → Hold 2026-04-21 50% win rate (6 calls)
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-04-08 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-02-27 Building track record
Needham — Reiterated
Buy → Buy 2026-02-27 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →